Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding (clinicaltrials.gov) - Mar 21, 2026 - P=N/A | N=10 | Recruiting | Sponsor: Chiesi Farmaceutici S.p.A. | Not yet recruiting ➔ Recruiting
Enrollment open • Fabry Disease • Genetic Disorders
|